Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

This review will focus on the process of amyloid-type protein aggregation. Amyloid fibrils are
an important hallmark of protein misfolding diseases and therefore have been investigated …

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

Alzheimer's disease (AD), due to its spread, has become a global health priority, and is
characterized by senile dementia and progressive disability. The main cause of AD and …

Current technological advancements in clinical and research settings have permitted a more
intensive and comprehensive understanding of Alzheimer's disease (AD). This development …

The first description of Alzheimer's disease (AD) was made in 1907 by Alois Alzheimer
(Allgemeine Zeitschrift fur Psyciatrie und Psychisch‐Gerichtliche Medizin 64, 3, 1907) …

Alzheimer's disease (AD) challenges our society with an annual estimated cost of $1.08
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …

Particulate ligands, including cholesterol crystals and amyloid fibrils, induce production of
interleukin 1β (IL-1β) dependent on the cytoplasmic sensor NLRP3 in atherosclerosis …